Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROCEPT BioRobotics (PRCT) Cash from Financing Activities (2020 - 2025)

PROCEPT BioRobotics (PRCT) has disclosed Cash from Financing Activities for 6 consecutive years, with $4.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities fell 97.4% to $4.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $11.2 million, a 93.79% decrease, with the full-year FY2025 number at $11.2 million, down 93.79% from a year prior.
  • Cash from Financing Activities was $4.4 million for Q4 2025 at PROCEPT BioRobotics, up from $1.1 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $174.1 million in Q3 2021 to a low of -$1.3 million in Q4 2022.
  • A 5-year average of $31.2 million and a median of $2.5 million in 2023 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: tumbled 304.66% in 2022, then skyrocketed 20764.74% in 2023.
  • PROCEPT BioRobotics' Cash from Financing Activities stood at $644000.0 in 2021, then crashed by 304.66% to -$1.3 million in 2022, then skyrocketed by 317.45% to $2.9 million in 2023, then soared by 5850.03% to $170.5 million in 2024, then crashed by 97.4% to $4.4 million in 2025.
  • Per Business Quant, the three most recent readings for PRCT's Cash from Financing Activities are $4.4 million (Q4 2025), $1.1 million (Q3 2025), and $4.4 million (Q2 2025).